ACCURAY (NASDAQ:ARAY)
5.54
0.05 (0.89%)
| ACCURAY (NASDAQ:ARAY) Delayed : |
| Previous Close |
$5.59 |
|
52 Week High |
$8.35 |
|
| Open |
$5.63 |
|
52 Week Low |
$3.78 |
| Day High |
$5.71 |
|
P/E |
554.00 |
| Day Low |
$5.52 |
|
EPS |
$0.01 |
| Volume |
108,733 |
|
|
|
| More ARAY Info:
Chart
SEC Filings
Profile
Historical
Options
|
Accuray Summary
Accuray Incorporated designs, develops, and sells the CyberKnife
system, an image-guided robotic radio surgery system for the treatment
of solid tumors.
Executives
Euan Thomson - CEO, President
John Adler Jr. - Founder
Links
http://www.accuray.com/
View All ReportsStreetInsider.com Reports on ARAY
-
Oct 29, 2009 05:06 PM
Accuray (ARAY) Misses Q1 EPS by 2c; Comments on FY Revenues
-
Oct 28, 2009 05:43 PM
Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
-
Oct 1, 2009 08:46 AM
Prostate Cancer Study Results Published on Patients Treated With Accuray's (ARAY) CyberKnife Radiosurgery
-
Aug 25, 2009 01:50 PM
Unusual 11 Mid-Day Movers 8/25: WLDN, CASM, CMRG, SPDE Higher; NED, GSL, ARAY, AIR Lower
-
Aug 25, 2009 09:32 AM
Morning Movers 8/25: WLDN, TUES, FNM, COCO, HGSI Higher; AIR, AMWD, ARAY, DAKT, NPD Lower
View All Reports
StreetInsider Reports on ARAY by Category
Comments on recent ARAY articles
Comments on ARAY
No comments are currently available.
on Oct 23, 2008
at 08:45 PM smart analysis Brilliant work Piper. Basically what you're saying is, "at first the units were only purchased by neurosurgeons, but the uses have expanded and now others are buying them, and they have a great product, that's why we're downgrading ARAY." The other brilliant part is, "focus on nearer-term indications such as lung and liver cancers while waiting for data on prostate applications to mature" This is a common misconception among everyone who didn't make it to page-4 of the annual report where a pretty color chart shows that since '06 lung and liver cancer treatments have tippled, pancreatic treatments have increased 50% and prostate treatments have increased almost 10-fold. Other than that, you were right on.
Article: Piper Jaffray & Co. Downgrades Accuray (ARAY) to Neutral